At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 985 enrolled
Drug / intervention
Moxifloxacin ophthalmic solution, 0.5% +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An Evaluation of the Safety and Efficacy of Moxifloxacin Ophthalmic Solution 0.5% Versus Ofloxacin Ophthalmic Solution 0.3% in the Treatment of Bacterial Conjunctivitis in Chinese Patients
In Brief
A Phase 3 clinical trial evaluating Moxifloxacin ophthalmic solution, 0.5% and Ofloxacin ophthalmic solution, 0.3% for Bacterial Conjunctivitis. Completed, enrolled 985 participants across 1 site.
Detailed Summary
The purpose of this study is to evaluate Moxifloxacin 0.5% relative to Ofloxacin 0.3% in the treatment of bacterial conjunctivitis in Chinese patients.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsBacterial Conjunctivitis
CountriesChina
Collaborators--
Timeline
Phase 3CompletedFinished
201220132014201520162017201820192020202120222023202420252026
First PostedApr 2012
Enrollment StartMay 2012
Primary CompletionApr 2014
TodayJul 2026
First PostedApr 10, 2012
Enrollment StartMay 1, 2012
Primary CompletionApr 1, 2014
TodayJul 2, 2026
Enrollment to primary: 1.9 yearsPosted 14.2 years ago
Interventions
Moxifloxacin ophthalmic solution, 0.5%drug
Ofloxacin ophthalmic solution, 0.3%drug